Home | EndoTODAY | EndoATLAS | Blog


[±â´É¼ºÁúȯ¿îµ¿ÇÐȸ ÆíÁý,ÀÇÁ¤ ½ÉÆ÷Áö¾ö]

2014³â 11¿ù 15ÀÏ ´ëÇѼÒÈ­±â±â´É¼ºÁúȯ,¿îµ¿ÇÐȸ ÆíÁýÀ§¿øȸ ¿öÅ©¼¥°ú ¿ªÇÐ ¹× ÀÓ»ó½ÃÇèÁöÇ¥ ¿¬±¸È¸ ½ÉÆ÷Áö¾öÀÌ ÀÖ¾ú½À´Ï´Ù. ù °­ÀÇ¿¡¼­ ÇѸ²ÀÇ´ë Çã¼± ¼±»ý´Ô²²¼­ "¾ÕÀ¸·Î ¸ðµç ³í¹®À» ¿Ïº®ÇÑ JATS XML·Î Á¦ÀÛÇÒ ÇÊ¿ä°¡ ÀÖ´Ù"°í °­Á¶ÇÏ¿´½À´Ï´Ù.


1. MeSH (Medical Subject Heading) À¯¿ë¼º°ú MTI ÀÌ¿ë MeSH ºÎ¿©¹æ¹ý (ÇѸ²´ëÇб³ ±è¼ö¿µ)

1) Controlled vocabulary Åë°è ¾îÈÖ. ³í¹®ÀÌ MeSH·Î »öÀεǾî ÀÖÀ¸¸é °Ë»öÀÇ ¹Î°¨µµ¿Í ƯÀ̵µ°¡ ¸ðµÎ ¿Ã¶ó°¨

2) Tree ±¸Á¶·Î µÇ¾î ÀÖ´Ù.


2. Peer reviewerÀÇ ½É»çÁö ÀÛ¼º¹ý (ÃÖÀÎÈ« ¿¬¼¼´ëÇб³ ¹Ì»ý¹°Çб³½Ç)

Cover letter¸¦ Àß ½á¾ß ÇÕ´Ï´Ù. ¾Æ·¡´Â ¿¹

"We submit the manuscript entitled as "..." for publication in the Nature as an original article. We believe that our study will be of wide popular interest to the readers of the Nature because our study is based on ...
This manuscript has never been published and is not currently under evaluation in any ogher peer-reviewed publication. All authors have read this manuscript and have approved for submission. There are no conflicts of interest.
Thank you for your kind consideration.
Sincerely yours, "

Figure legend´Â ÇöÀçÇüÀ¸·Î ±â¼úµÇ¾î¾ß ÇÕ´Ï´Ù.

¹®Á¦Á¡. ±âÁ¸ À̷аú »ó¹ÝµÈ ¿¬±¸´Â rejectµÇ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. Louis PillemerÀÇ º¸Ã¼ alternative pathway ÀÌ·ÐÀº óÀ½ ±â°í ´ç½Ã ¹Þ¾Æµé¿©ÁöÁö ¾Ê¾Ò½À´Ï´Ù. ÀÌ·Î ÀÎÇÏ¿© 3³â ÈÄ ¿¬±¸ÀÚ°¡ ÀÚ»ìÇÏ¿´´Ù°í ÇÕ´Ï´Ù. ÀÏÁ¾ÀÇ intellectual suppressionÀÎ °ÍÀÌÁö¿ä.

¹®Á¦Á¡. À¯·É½É»çÀÚ. °¡Â¥ e-mailÀ» ÀÌ¿ëÇÏ¿© ÀÚ±â ÀÚ½ÅÀ» ÀÚ±â ³í¹® reviewer·Î ¼±Á¤ÇÑ ¿¹°¡ ÀÖ¾ú´Ù°í ÇÕ´Ï´Ù.


3. JNM ¿µÇâ·ÂÁöÇ¥ Çâ»óÀ» À§ÇÑ Àå±â Àü·« (¼­¿ï´ëÇб³ ±è³ª¿µ)

JNM ¼º°ø Àü·« ºÐ¼®

Áú ÁÁ°í citationÀÌ Àß µÉ review articleÀÇ Á¶°Ç


4. ºò µ¥ÀÌŸ¶õ ¹«¾ùÀΰ¡? (¼­¿ï¾Æ»êº´¿ø ÀÌÁ¤º¹) 4 V's : volume, velocity, variety, veracity

Some of critical issues

Big data problems such as heterogeneity, noise accumulation, spurious correlation, and incidental endogeneity, sparsity, in addition to balancing the statistical accuracy and computational efficiency.


5. ¼ÒÈ­±â ±â´É¼º Áúȯ¿¡¼­ÀÇ ºòµ¥ÀÌÅÍ ºÐ¼® (¼­¿ï¾Æ»êº´¿ø Á¤±â¿í)

The big data president

Finding the missing link fot big biomedical data (JAMA. 2014 Jun 25;311(24):2479-80.)

¿©·¯°¡Áö °í·ÁÇÒ Á¡


6. °ø°ø µ¥ÀÌÅÍ °³¹æ°ú °ü·ÃµÈ ½ÉÆò¿øÀÇ ºòµ¥ÀÌÅÍ È°¿ë (½ÉÆò¿ø ±è·Ï¿µ)

1³â û±¸ÀÚ·á 4,800¸¸¸í (1³â¿¡ ÇѹøÀÌ¶óµµ º´¿øÀ» »ç¿ëÇÑ ±¹¹ÎÀÇ ¼ö)

û±¸ÀڷḦ ÀÌ¿ëÇϱâ À§Çؼ­´Â Á¶ÀÛÀû Á¤ÀÇ°¡ Áß¿äÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ³úÁ¹Áß ¹ß»ý·ü ¿¬±¸¿¡¼­ Á¶ÀÛÀû Á¤ÀÇ(ÄÚµå, ÀÔ¿ø, CT ¶Ç´Â MRI, Ç×Ç÷¼ÒÆÇÁ¦)¿¡ µû¶ó ÄÚµå·Î ¼±ÅÃµÈ È¯ÀÚ¸¦ °É·¯º¸¾Ò´õ´Ï óÀ½ ¸®½ºÆ®µÈ ȯÀÚÀÇ 30%°¡ Å»¶ôµÇ¾ú½À´Ï´Ù.

°³ÀÎÁ¤º¸ È°¿ë¿¡ °üÇÑ ¹ýÀû Á¦¾àÀÌ ÀÖ½À´Ï´Ù. ¸í¼¼¼­ÀϷùøÈ£°¡ °³ÀÎÁ¤º¸°¡ ¾Æ´Ñ key·Î È°¿ëÇÒ ¼ö ÀÖ´ÂÁö °ËÅäÁßÀÔ´Ï´Ù.


7. ºòµ¥ÀÌÅÍ ºÐ¼®µµ±¸¸¦ È°¿ëÇÑ Àӻ󿬱¸ (SAS Korea ÃÖº´Á¤)

Consulting ȸ»çÀÇ Á¦Ç° È«º¸½Ã°£ °°¾Ò½À´Ï´Ù. ±âºÐÀÌ º°·Î ÁÁÁö ¾Ê¾Ò½À´Ï´Ù. ¸¹ÀÌ ÁÁÁö ¾Ê¾Ò½À´Ï´Ù.


8. º¸Çè¼ö°¡Á¤Ã¥º¯È­¿¡ ´ëÀÀÇϱâ À§ÇÑ ÇÐȸÀÇ ¿ªÇÒ (¼øõÇâ´ëÇб³ º¸°ÇÇàÁ¤°æ¿µÇаú ¹ÎÀμø)

¿ä¾ç±Þ¿©ºñ¿ë »êÁ¤Á¦µµ (Áø·áº¸¼ö ÁöºÒÁ¦µµ)

1) »ó´ë°¡Ä¡Á¡¼öÁ¦µµ (ÇàÀ§º° ¼ö°¡Á¦) : ÀÇ»ç¾÷¹«·®, Áø·áºñ¿ë, À§Çèµµ. ÇöÀç 2Â÷ »ó´ë°¡Ä¡¿¬±¸°¡ ³¡³­ »óÅÂÀÓ. °úº° pie¸¦ °íÁ¤ÇÏ´ø °ú°Å ¹æ½ÄÀ» ¹Ù²ã¼­ À¯Çüº° ÃÑÁ¡°íÁ¤ »êÃâüÁ¦·Î º¯°æµÊ. --> 2015³â 7¿ù¿¡ Å« º¯È­°¡ ¿Ã °ÍÀ¸·Î »ý°¢µÊ. ÇàÀ§ºÐ·ùü°è°¡ ´Þ¶óÁú °Í °°À½.

2) ½ÅÆ÷°ý¼ö°¡ ½Ã¹ü»ç¾÷: ÀÏ´ç Áø·áºñ °³³äÀÇ µµÀÔ, ÇàÀ§º°¼ö°¡Á¦ ¿ä¼Ò¸¦ ÀûÀýÈ÷ È°¿ë (º´¿ø ºñ¿ë°ú ÀÇ»çºñ¿ëÀÇ ±¸ºÐ), ÁöºÒÁ¦µµ °³Æí ¹× ±Þ¿©¹üÀ§ È®´ë, ÀÏ´ç¼ö°¡ µµÀÔ --> 2016³â¿¡´Â ½Å¸ðµ¨ÀÌ °³¹ßµÉ ¿¹Á¤. Àü¸é DRG·Î °ð ¹Ù·õ ¿¹Á¤ÀÔ´Ï´Ù.

cf) ¿ä¾ç±â°ü ÆгÎÁ¦µµ: ´ëÇ¥º´¿øÀ» ¼±Á¤ÇÏ¿© Ç¥ÁØÈ­µÈ ¿ø°¡¸¦ »êÃâÇÏ´Â ¹æ½Ä


i) ¼±Á¦Àû ´ëÀÀ: »ó´ë°¡Ä¡ °³Á¤¿¡ ´ëÀÀÇϱâ À§ÇÑ ¼±Á¦Àû ÀÚ·á¼öÁý ¹× °³¼± ¿¬±¸ ÇÊ¿äÇÕ´Ï´Ù. ¿¬±¸°á°ú°¡ ³ª¿À¸é ¹Ù²Ù±â ¾î·Æ°í ¿¬±¸´Ü°è¿¡ ´ëÀÀÇØ¾ß ÇÑ´Ù.

ii) Àü·«Àû ´ëÀÀ: (½ÉÆò¿øÀÌ ¾Æ´Ï¶ó) º¹ÁöºÎ¿¡ ÇÕ¸®ÀûÀÎ Á¦¾ÈÀ» ÇØ¾ß ÇÕ´Ï´Ù.

iii) ü°èÀû ´ëÀÀ: ÇàÁ¤Àû support¸¦ À§ÇÑ ÀÎÀûÀÚ¿ø°ú Á¶Á÷ÀÌ ÇÊ¿äÇÏ´Ù.


[2014-11-15. ÀÇÇù½Å¹®] ¿À´Ã ÀÇÇù½Å¹®¿¡ Â÷Àç¸í ±³¼ö´ÔÀÇ ÀÎÅÍºä ±â»ç°¡ ½Ç·È½À´Ï´Ù (¸µÅ©). ÃàÇÏÇÕ´Ï´Ù. Â÷Àç¸í ±³¼ö´ÔÀº EndoTODAYÀÇ ÇϺÎÀ§Àå°ü main consultantÀ̽ʴϴÙ.

Â÷Àç¸í ±³¼ö´Ô ÁÖÀå¿¡ µ¿ÀÇÇÕ´Ï´Ù¸¸... ÇÑ ¸¶µð µ¡ºÙÀÌ°í ½Í½À´Ï´Ù. ¿ì¸®³ª¶ó¿¡¼­ ´ëÀå³»½Ã°æÀº ³Ê¹« Àû°Ô ÇÏ´Â Ãø¸éÀÌ ÀÖ°í ³Ê¹« ¸¹ÀÌ ÇÏ´Â Ãø¸éÀÌ ÀÖ½À´Ï´Ù. ´ëÀå¾Ï °ËÁø ´ë»óÀε¥ ´ëÀå³»½Ã°æÀ» Çѹøµµ ¾È ÇØ º» »ç¶÷ÀÌ ¸¹½À´Ï´Ù. ³Ê¹« Àû°Ô ÇÏ´Â Ãø¸éÀÔ´Ï´Ù. ´ëÀå³»½Ã°æÀ» ¹Þ°í ¿ëÁ¾ÀÌ ¹ß°ßµÈ »ç¶÷Àº ¸Å³â Àç°ËÇÏ´Â °æ¿ìµµ Á¾Á¾ ¹ß°ßµË´Ï´Ù. ³Ê¹« ¸¹ÀÌ ÇÏ´Â Ãø¸éÀÌÁö¿ä. ÀûÀýÇÑ ¹æÇâÀ¸·Î ÀÚ¸®¸¦ Àâ¾Æ¾ß ÇÒ °Í °°½À´Ï´Ù. ÇÑ ¹øµµ ¾È ¹ÞÀº »ç¶÷Àº °Ë»ç¸¦ ¹Þµµ·Ï À¯µµÇÏ°í, ³Ê¹« ÀÚÁÖ ¹Þ´Â »ç¶÷Àº Á» ¸»·Á¾ß ÇÏ°Ú½À´Ï´Ù.

2014³â Chicago DDW¿¡ °¬À» ¶§ "Maximizing colonoscopy quality"¶ó´Â ½ÉÆ÷Áö¾ö¿¡ Âü°¡ÇÑ ÀûÀÌ ÀÖ½À´Ï´Ù. ¹Ì±¹ »ç¶÷ÀÌ »ý°¢ÇÏ´Â quality indicator¿¡ ´ëÇÑ °­¿¬(°­»ç: Philip Schoenfeld)ÀÌ ÀÖ¾ú½À´Ï´Ù. ¹Ì±¹¿¡¼­µµ indicationÀÌ µÇÁö ¾Ê´Âµ¥ ´ëÀå³»½Ã°æ °Ë»ç¸¦ ³Ê¹« ÀÚÁÖ ÇÏ´Â »ç¶÷ÀÌ ÀÖ´Ù°í ÇÕ´Ï´Ù. ¿ì¸®³ª¶ó´Â ´õ ½ÉÇÏÁö¸¸... ´ç½Ã °­ÀÇ¿¡¼­ ¾ð±ÞµÈ quality indicatorµéÀº ¾Æ·¡¿Í °°¾Ò½À´Ï´Ù.

  1. Adenoma detection rate (ADR) >25% (³²ÀÚ¿¡¼­´Â 30%, ¿©ÀÚ´Â 20%). ADRÀ» ³ôÀ̱â À§Çؼ­ (1) withdrawal timeÀ» ´Ã¸®°í, (2) ÀåÁ¤°áÀ» Çâ»ó½ÃÅ°°í, (3) cecum¿¡¼­ retroflectionÀ» ÇÏ´Â °ÍÀÌ ÃßõµË´Ï´Ù.
  2. Documented appropriate indication for colonoscopy > 80%. There is no clear indication for the early repeated examination in 23.5%.
  3. Adequate bowel preparation in outpatient setting > 85%. SplittingÀÌ ÁÁ½À´Ï´Ù.
  4. Cecal intubation rate with photodocumentation > 95%
  5. Documented appropriate recommendation for next colonoscopy > 90%. Hyperplastic polypÀ» Á¦°ÅÇÑ ÈÄ 5³â À̳»¿¡ Àç°ËÇÏ´Â °Í±îÁö ¹®Á¦¸¦ »ï°í ÀÖ½À´Ï´Ù. ¿ì¸®¿Í ´Þ¶óµµ ³Ê¹« ´Ù¸£³×¿ä.
  6. Average withdrawal time > 6 minutes. Withdrawal time¿¡ ´ëÇؼ­´Â 6ºÐÀ̶ó´Â ¼ýÀÚ°¡ misquotedµÇ°í ÀÖ½À´Ï´Ù. Every single colonoscopy°¡ Ç×»ó 6ºÐ ÀÌ»óÀÌ µÇ¾î¾ß ÇÑ´Ù´Â ¶æÀº ¾Æ´Õ´Ï´Ù. ÀåÁ¤°áÀÌ ÁÁ°í °üÂûÀÌ ½¬¿î °Ë»ç´Â 6ºÐº¸´Ù ª°Ô ³¡³¯ ¼ö ÀÖ½À´Ï´Ù.
  7. Perforation < 1/1000
  8. Postpolypectomy bleeding < 1%


[Âü°íÀÚ·á]

1) ±â´É¼º,¿îµ¿Áúȯ ÇмúÇà»ç on-line Áß°è

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà